SAN DIEGO, June 4, 2015 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTC:AXIM) is a unique biotechnology corporation with a focus on global research, development and production of pharmaceutical, nutraceutical, food and cosmetic products – all derived or related to hemp. The Company's core belief is responsibility for environmental stewardship combined with development of innovative products to address current conditions with no known effective treatment including: Parkinson's disease, Alzheimer's disease / dementia, ADHD (attention deficit hyperactivity disorder), PTSD, autism, MS, spasticity, pain, RLS (restless leg syndrome), glaucoma, IBD, IBS and Crohn's disease.
"We are very proud to be able to create a highly diversified corporate entity working on numerous ground-breaking bio-technological innovations," states George E. Anastassov, MD, DDS, MBA and CEO of AXIM Biotech. We believe that there is no comparable company in the biosciences space and especially as related to cannabinoids and hemp derived products. Not only we are working on issues for which there are currently no effective solutions but we are doing it while being environmentally and fiscally conservative."
The cannabis-based pharmaceutical market is evolving. AXIM Biotech is producing a broad scope of proprietary delivery mechanisms for the introduction of natural components of the cannabis (hemp) plant known as cannabinoids (e.g. CBD, CBG, THC, etc.). AXIM Biotech's intellectual property, to date, includes many patent applications in various stages of application, with additional inventions to be filed soon, as well as trademark applications; many of them are approved trademarks. Any of AXIM's products are supported by solid intellectual property prior to being produced and distributed worldwide.
As the exclusive license recipient to the world's first controlled-release chewing gum containing cannabinoids, AXIM Biotechnologies is pursuing two global markets: food with CanChew® Plus and pharmaceutical with MedChew RX™. Award-winning CanChew® gum, a food product, is available today; CanChew® Plus is planned to be available soon. MedChew RX™ is undergoing clinical trials with the intent for obtaining FDA and EMA registration as a pharmaceutical compound for treatment of pain and spasticity.
Another "world's first" are AXIM Biotech's cannabigerol (CBG) ORAXIMAX™ oral care and RENECANN™ cosmetics retail products timed for delivery in the 3rd quarter of this year. These all-natural CBG retail products from AXIM Biotech will be priced similarly to other retail products in categories including:
- Toothpaste
- Mouthwash
- Dentifrice
- Oral Gel (for minor cuts and sores)
- Diaper Rash Cream
- Moisturizers
- Lotions
- Lip Balm
- Shampoo
- Conditioner
- Body Wash
- Day Cream
- Night Cream
- Eye Cream
Photos accompanying this release are available at:
http://www.globenewswire.com/newsroom/prs/?pkgid=33481
http://www.globenewswire.com/newsroom/prs/?pkgid=33483
http://www.globenewswire.com/newsroom/prs/?pkgid=33484
This photo is available at Newscom, www.newscom.com, and via AP PhotoExpress. http://www.globenewswire.com/newsroom/prs/?pkgid=33482
AXIM Biotech products are produced from pharmaceutical grade cannabinoids. These are tested and free of heavy metals, pesticides, fungi or bacteria.
Global markets that AXIM Biotech addresses include: alternative energy, manufacturing, food, nutraceuticals, pharmaceuticals, phytoplant/botanicals, and research and development.
An additional area of focus for AXIM Biotech is community outreach. Adopt-A-Soldier Platoon, Inc. was selected as a beneficiary by AXIM Biotech in 2015. The Company will donate CanChew® gum at the organization's July 4 Warfighters Independence Weekend. For ways to support service members through Adopt-a-Soldier Platoon, Inc. visit http://www.adoptasoldierplatoon.org.
AXIM Biotech has been featured by media outlets including: FOX Business, MainStreet.com, MJ Freeway, Chemical & Engineering News, Dental Tribune, Pharmaceutical Commerce, Dental Products Report and MJI News. For more information, visit AXIM Biotech's website.
To arrange for media interviews, contact Andrew Hard, Public Relations Spokesperson, at Andrew.Hard@CMWmedia.com or call 858-380-5478.
About AXIM:
AXIM Biotechnologies, Inc. (OTC:AXIM) is an innovative biotechnology Company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSURE
AXIM Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The Company does grow, sell, and distribute hemp-based products.
North American Address:
18 East 50th Street, 5 Floor
New York, NY 10022
+1 844 294 6246
European Address:
Boelewerf 32, Unit 3
2987 VD Ridderkerk, The Netherlands
+31 10 8209 227
